Radiopharm Theranostics (ASX:RAD) Announces Participation in TD Cowen Healthcare Conference

February 24, 2025 06:00 PM AEDT | By Sonal Goyal

Google News:

Radiopharm Theranostics (ASX:RAD) Announces Participation in TD Cowen Healthcare Conference — Image source: Company update

Recent News

Volvo Cars and HCLTech Collaborate to Drive Engineering Transformation

International Paper To Explore Building a New State-of-the-Art Sustain...

Cantor downgrades air taxi company Joby after sharp stock rally

Epiminder Announces Publication of Landmark Clinical Trial Confirming...

Highlights

Radiopharm Theranostics will attend TD Cowen’s 45th Annual Healthcare Conference.

The event will take place from 3–5 March 2024 at the Boston Marriott Copley Place in Massachusetts, USA.

The conference offers a platform for Radiopharm Theranostics to showcase its investment proposition to a global audience of investors and industry peers.

Radiopharm Theranostics Limited (ASX:RAD), an Australian clinical-stage radiotherapeutics company, has announced its participation in TD Cowen’s 45^th Annual Healthcare Conference. The conference is scheduled to take place from 3 to 5 March 2024, at the Boston Marriott Copley Place in Boston, Massachusetts, USA.

Riccardo Canevari, RAD’s MD and CEO, will present on on Wednesday, 5 March 2025, 1:10 AM AEDT, outlining RAD’s investment proposition to attending investors.

The TD Cowen Annual Healthcare Conference is a prominent event that brings together over 400 public and private companies from across the healthcare and investment spectrum. The conference features fireside chats, presentations, discussions and corporate panels, providing a platform for companies to discuss key trends and issues with investors and industry peers.

Radiopharm Theranostics, listed on the ASX (RAD) since 2021, is a clinical-stage radiotherapeutics company focused on radiopharmaceuticals for diagnostic and therapeutic cancer treatments. Its pipeline includes peptides, small molecules, and monoclonal antibodies in Phase I and II trials for brain, lung, breast, and pancreas cancers, aiming to be first-to-market or best-in-class.

RAD shares traded at AU$0.024 per share on 24 February 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.